⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

HOTH News

Hoth Therapeutics, Inc. Common Stock

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities